Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING

v3.20.1
SEGMENT REPORTING
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]

NOTE 12 — SEGMENT REPORTING


In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has two reportable segments: BioSig Technologies, Inc. (parent) and ViralClear Pharmaceuticals, Inc.


Information concerning the operations of the Company’s reportable segments is as follows:


Summary Statement of Operations for the three months ended March 31, 2020:


   

BioSig

   

ViralClear

         
   

Technologies, Inc

   

Pharmaceuticals, Inc.

   

Total

 

Operating expenses:

                       

Research and development

  $ 1,327,003     $ 3,599,711     $ 4,926,714  

General and administrative

    3,819,438       4,035,782       7,855,220  

Depreciation and amortization

    21,015       -       21,015  

    Total operating expenses

    5,167,456       7,635,493       12,802,949  
                         

Loss from Operations

    (5,167,456 )     (7,635,493 )     (12,802,949 )
                         

Other income:

                       

Interest income

    25,411       14,165       39,576  
                         

Net loss

    (5,142,045 )     (7,621,328 )     (12,763,373 )
                         

Preferred stock dividend

    (4,618 )     -       (4,618 )
                         

Net loss attributable to common stockholder

    (5,146,663 )     (7,621,328 )     (12,767,991 )
                         

Non-controlling interest

    -       1,427,813       1,427,813  
                         

Net loss attributable to BioSig Technologies, Inc.

  $ (5,146,663 )   $ (6,193,515 )   $ (11,340,178 )